Ranjana Advani

Ranjana Advani is a leading clinical investigator who has dedicated her career to developing better therapies for T-cell and NK/T-cell lymphomas. Her work spans studies of novel immunotherapies including PD-1 checkpoint inhibitors and PI3K inhibitors in NK/T-cell lymphoma, and she has contributed to understanding why these EBV-driven lymphomas are potentially responsive to immune-based approaches. She is a recognized leader in CTCL and NK/T-cell lymphoma clinical research.